U.S. markets close in 57 minutes
  • S&P 500

    3,456.96
    +13.84 (+0.40%)
     
  • Dow 30

    28,350.71
    +41.92 (+0.15%)
     
  • Nasdaq

    11,571.00
    +54.51 (+0.47%)
     
  • Russell 2000

    1,613.59
    -4.12 (-0.25%)
     
  • Crude Oil

    40.11
    -1.59 (-3.81%)
     
  • Gold

    1,927.10
    +11.70 (+0.61%)
     
  • Silver

    25.18
    +0.20 (+0.82%)
     
  • EUR/USD

    1.1867
    +0.0038 (+0.32%)
     
  • 10-Yr Bond

    0.8080
    +0.0110 (+1.38%)
     
  • GBP/USD

    1.3162
    +0.0215 (+1.66%)
     
  • USD/JPY

    104.5200
    -0.9500 (-0.90%)
     
  • BTC-USD

    12,765.78
    +1,708.77 (+15.45%)
     
  • CMC Crypto 200

    255.95
    +11.06 (+4.51%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Imagine Holding ChemoCentryx (NASDAQ:CCXI) Shares While The Price Zoomed 652% Higher

Simply Wall St
·3 mins read

ChemoCentryx, Inc. (NASDAQ:CCXI) shareholders might be concerned after seeing the share price drop 20% in the last quarter. But over five years returns have been remarkably great. Indeed, the share price is up a whopping 652% in that time. Arguably, the recent fall is to be expected after such a strong rise. But the real question is whether the business fundamentals can improve over the long term.

We love happy stories like this one. The company should be really proud of that performance!

Check out our latest analysis for ChemoCentryx

Because ChemoCentryx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So it makes a lot of sense to check out what analysts think ChemoCentryx will earn in the future (free profit forecasts).

A Different Perspective

It's good to see that ChemoCentryx has rewarded shareholders with a total shareholder return of 601% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 50% per year), it would seem that the stock's performance has improved in recent times. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with ChemoCentryx , and understanding them should be part of your investment process.

But note: ChemoCentryx may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.